Surge Period Expected for ERCP and PTC Devices Market

Currently expected to be valued at $590 million by the end of 2020, the global endoscopic retrograde cholangiopancreatography (ERCP) and percutaneous transhepatic cholangiography (PTC) devices market is anticipated to grow at a compound annual growth rate (CAGR) of 3.5 despite the negative impact of COVID-19, as these devices are necessary to resolve obstructions of the pancreatic and biliary ducts, which can lead to severe consequences if left untreated. Additionally, advancements in ERCP procedures resulting in fewer complications will contribute to the growth of this market. By 2021, worldwide data and analytics company GlobalData anticipates the start of a “surge period” for this market, to make up for sales that were postponed in 2020. However, the surge will not offset revenue losses until 2022. 
 
The company’s recent report, “ERCP & PTC Devices, Global Outlook, 2015-2030” indicates that 9 percent of revenue was lost in 2020 due to COVID-19, as many surgical procedures were postponed in Q2 2020. However, the ERCP and PTC devices market was not as severely impacted as other markets such as aesthetic injectables or bariatric surgery, since a majority of cases are considered to be urgent and were unable to be postponed during the pandemic.  
 
Eric Chapman, a senior medical devices analyst at GlobalData, commented: “In Q1 2020, elective procedures were postponed from around mid-March (two out of 12 weeks), however this two week period did not severely impact the overall sales of ERCP and PTC devices. By Q2 2020, as the number of new COVID-19 cases had reached a peak and many procedures had been cancelled or postponed, the market was down 27 percent. Boston Scientific Corp. is the market leader for ERCP and PTC devices sales, followed by Cook Medical, Olympus Corp., Merit Medical System,s and ConMed Corp. As such, these companies lost the most revenue due to the impact of COVID-19.”
 
GlobalData expects these players to retain their market position after the market recovers from the pandemic. Smaller manufacturers will continue to have a difficult time winning market share from these companies, especially in the United States.